Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

Pradenas, Edwards|||0000-0001-5162-8920; Trinité, Benjamin|||0000-0003-3809-042X; Urrea, Víctor|||0000-0002-2577-856X; Marfil, Sílvia|||0000-0003-0139-5000; Tarrés-Freixas, Ferran|||0000-0002-1569-0126; Ortiz, Raquel|||0000-0002-6919-2026; Rovirosa, Carla|||0000-0002-7111-0253; Rodon, Jordi|||0000-0002-1032-9091; Vergara-Alert, Júlia|||0000-0001-7484-444X; Segalés Coma, Joaquim|||0000-0002-1539-7261; Guallar, Victor|||0000-0002-4580-1114; Valencia, Alfonso|||0000-0002-8937-6789; Izquierdo Useros, Nuria|||0000-0002-1039-1821; Noguera-Julian, Marc|||0000-0002-6194-1395; Carrillo, Jorge|||0000-0003-0221-5948; Paredes, Roger|||0000-0002-6553-691X; Mateu, Lourdes|||0000-0001-7223-7611; Chamorro, Anna; Toledo, Ruth; Massanella, Marta|||0000-0002-3326-151X; Clotet Sala, Bonaventura|||0000-0003-3232-4598; Blanco, Julià|||0000-0002-2225-0217

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

To understand the determinants of long-term immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the concurrent impact of vaccination and emerging variants, we follow a prospective cohort of 332 patients with coronavirus disease 2019 (COVID-19) over more than a year a...

Descripción completa

Detalles Bibliográficos
Autores:	Pradenas, Edwards\|\|\|0000-0001-5162-8920, Trinité, Benjamin\|\|\|0000-0003-3809-042X, Urrea, Víctor\|\|\|0000-0002-2577-856X, Marfil, Sílvia\|\|\|0000-0003-0139-5000, Tarrés-Freixas, Ferran\|\|\|0000-0002-1569-0126, Ortiz, Raquel\|\|\|0000-0002-6919-2026, Rovirosa, Carla\|\|\|0000-0002-7111-0253, Rodon, Jordi\|\|\|0000-0002-1032-9091, Vergara-Alert, Júlia\|\|\|0000-0001-7484-444X, Segalés Coma, Joaquim\|\|\|0000-0002-1539-7261, Guallar, Victor\|\|\|0000-0002-4580-1114, Valencia, Alfonso\|\|\|0000-0002-8937-6789, Izquierdo Useros, Nuria\|\|\|0000-0002-1039-1821, Noguera-Julian, Marc\|\|\|0000-0002-6194-1395, Carrillo, Jorge\|\|\|0000-0003-0221-5948, Paredes, Roger\|\|\|0000-0002-6553-691X, Mateu, Lourdes\|\|\|0000-0001-7223-7611, Chamorro, Anna, Toledo, Ruth, Massanella, Marta\|\|\|0000-0002-3326-151X, Clotet Sala, Bonaventura\|\|\|0000-0003-3232-4598, Blanco, Julià\|\|\|0000-0002-2225-0217
Tipo de recurso:	artículo
Fecha de publicación:	2022
País:	España
Institución:	Universitat Autònoma de Barcelona
Repositorio:	Dipòsit Digital de Documents de la UAB
Idioma:	inglés
OAI Identifier:	oai:ddd.uab.cat:257275
Acceso en línea:	https://ddd.uab.cat/record/257275 https://dx.doi.org/urn:doi:10.1016/j.xcrm.2022.100523
Access Level:	acceso abierto
Palabra clave:	B cell memory Durability Half-life Humoral response Neutralizing antibodies Pseudovirus SARS-CoV-2 Severity Variants of concern

id	ES_a8f83d0dddbf93cae68df097d746ee99
oai_identifier_str	oai:ddd.uab.cat:257275
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infectionPradenas, Edwards\|\|\|0000-0001-5162-8920Trinité, Benjamin\|\|\|0000-0003-3809-042XUrrea, Víctor\|\|\|0000-0002-2577-856XMarfil, Sílvia\|\|\|0000-0003-0139-5000Tarrés-Freixas, Ferran\|\|\|0000-0002-1569-0126Ortiz, Raquel\|\|\|0000-0002-6919-2026Rovirosa, Carla\|\|\|0000-0002-7111-0253Rodon, Jordi\|\|\|0000-0002-1032-9091Vergara-Alert, Júlia\|\|\|0000-0001-7484-444XSegalés Coma, Joaquim\|\|\|0000-0002-1539-7261Guallar, Victor\|\|\|0000-0002-4580-1114Valencia, Alfonso\|\|\|0000-0002-8937-6789Izquierdo Useros, Nuria\|\|\|0000-0002-1039-1821Noguera-Julian, Marc\|\|\|0000-0002-6194-1395Carrillo, Jorge\|\|\|0000-0003-0221-5948Paredes, Roger\|\|\|0000-0002-6553-691XMateu, Lourdes\|\|\|0000-0001-7223-7611Chamorro, AnnaToledo, RuthMassanella, Marta\|\|\|0000-0002-3326-151XClotet Sala, Bonaventura\|\|\|0000-0003-3232-4598Blanco, Julià\|\|\|0000-0002-2225-0217B cell memoryDurabilityHalf-lifeHumoral responseNeutralizing antibodiesPseudovirusSARS-CoV-2SeverityVariants of concernTo understand the determinants of long-term immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the concurrent impact of vaccination and emerging variants, we follow a prospective cohort of 332 patients with coronavirus disease 2019 (COVID-19) over more than a year after symptom onset. We evaluate plasma-neutralizing activity using HIV-based pseudoviruses expressing the spike of different SARS-CoV-2 variants and analyze them longitudinally using mixed-effects models. Long-term neutralizing activity is stable beyond 1 year after infection in mild/asymptomatic and hospitalized participants. However, longitudinal models suggest that hospitalized individuals generate both short- and long-lived memory B cells, while the responses of non-hospitalized individuals are dominated by long-lived B cells. In both groups, vaccination boosts responses to natural infection. Long-term (. 22022-01-0120222022-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/257275https://dx.doi.org/urn:doi:10.1016/j.xcrm.2022.100523reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengInstituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI17/01518Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI20/00093Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18/01332open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2572752026-06-06T12:50:31Z
dc.title.none.fl_str_mv	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
title	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
spellingShingle	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection Pradenas, Edwards\|\|\|0000-0001-5162-8920 B cell memory Durability Half-life Humoral response Neutralizing antibodies Pseudovirus SARS-CoV-2 Severity Variants of concern
title_short	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
title_full	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
title_fullStr	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
title_full_unstemmed	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
title_sort	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
dc.creator.none.fl_str_mv	Pradenas, Edwards\|\|\|0000-0001-5162-8920 Trinité, Benjamin\|\|\|0000-0003-3809-042X Urrea, Víctor\|\|\|0000-0002-2577-856X Marfil, Sílvia\|\|\|0000-0003-0139-5000 Tarrés-Freixas, Ferran\|\|\|0000-0002-1569-0126 Ortiz, Raquel\|\|\|0000-0002-6919-2026 Rovirosa, Carla\|\|\|0000-0002-7111-0253 Rodon, Jordi\|\|\|0000-0002-1032-9091 Vergara-Alert, Júlia\|\|\|0000-0001-7484-444X Segalés Coma, Joaquim\|\|\|0000-0002-1539-7261 Guallar, Victor\|\|\|0000-0002-4580-1114 Valencia, Alfonso\|\|\|0000-0002-8937-6789 Izquierdo Useros, Nuria\|\|\|0000-0002-1039-1821 Noguera-Julian, Marc\|\|\|0000-0002-6194-1395 Carrillo, Jorge\|\|\|0000-0003-0221-5948 Paredes, Roger\|\|\|0000-0002-6553-691X Mateu, Lourdes\|\|\|0000-0001-7223-7611 Chamorro, Anna Toledo, Ruth Massanella, Marta\|\|\|0000-0002-3326-151X Clotet Sala, Bonaventura\|\|\|0000-0003-3232-4598 Blanco, Julià\|\|\|0000-0002-2225-0217
author	Pradenas, Edwards\|\|\|0000-0001-5162-8920
author_facet	Pradenas, Edwards\|\|\|0000-0001-5162-8920 Trinité, Benjamin\|\|\|0000-0003-3809-042X Urrea, Víctor\|\|\|0000-0002-2577-856X Marfil, Sílvia\|\|\|0000-0003-0139-5000 Tarrés-Freixas, Ferran\|\|\|0000-0002-1569-0126 Ortiz, Raquel\|\|\|0000-0002-6919-2026 Rovirosa, Carla\|\|\|0000-0002-7111-0253 Rodon, Jordi\|\|\|0000-0002-1032-9091 Vergara-Alert, Júlia\|\|\|0000-0001-7484-444X Segalés Coma, Joaquim\|\|\|0000-0002-1539-7261 Guallar, Victor\|\|\|0000-0002-4580-1114 Valencia, Alfonso\|\|\|0000-0002-8937-6789 Izquierdo Useros, Nuria\|\|\|0000-0002-1039-1821 Noguera-Julian, Marc\|\|\|0000-0002-6194-1395 Carrillo, Jorge\|\|\|0000-0003-0221-5948 Paredes, Roger\|\|\|0000-0002-6553-691X Mateu, Lourdes\|\|\|0000-0001-7223-7611 Chamorro, Anna Toledo, Ruth Massanella, Marta\|\|\|0000-0002-3326-151X Clotet Sala, Bonaventura\|\|\|0000-0003-3232-4598 Blanco, Julià\|\|\|0000-0002-2225-0217
author_role	author
author2	Trinité, Benjamin\|\|\|0000-0003-3809-042X Urrea, Víctor\|\|\|0000-0002-2577-856X Marfil, Sílvia\|\|\|0000-0003-0139-5000 Tarrés-Freixas, Ferran\|\|\|0000-0002-1569-0126 Ortiz, Raquel\|\|\|0000-0002-6919-2026 Rovirosa, Carla\|\|\|0000-0002-7111-0253 Rodon, Jordi\|\|\|0000-0002-1032-9091 Vergara-Alert, Júlia\|\|\|0000-0001-7484-444X Segalés Coma, Joaquim\|\|\|0000-0002-1539-7261 Guallar, Victor\|\|\|0000-0002-4580-1114 Valencia, Alfonso\|\|\|0000-0002-8937-6789 Izquierdo Useros, Nuria\|\|\|0000-0002-1039-1821 Noguera-Julian, Marc\|\|\|0000-0002-6194-1395 Carrillo, Jorge\|\|\|0000-0003-0221-5948 Paredes, Roger\|\|\|0000-0002-6553-691X Mateu, Lourdes\|\|\|0000-0001-7223-7611 Chamorro, Anna Toledo, Ruth Massanella, Marta\|\|\|0000-0002-3326-151X Clotet Sala, Bonaventura\|\|\|0000-0003-3232-4598 Blanco, Julià\|\|\|0000-0002-2225-0217
author2_role	author author author author author author author author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	B cell memory Durability Half-life Humoral response Neutralizing antibodies Pseudovirus SARS-CoV-2 Severity Variants of concern
topic	B cell memory Durability Half-life Humoral response Neutralizing antibodies Pseudovirus SARS-CoV-2 Severity Variants of concern
description	To understand the determinants of long-term immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the concurrent impact of vaccination and emerging variants, we follow a prospective cohort of 332 patients with coronavirus disease 2019 (COVID-19) over more than a year after symptom onset. We evaluate plasma-neutralizing activity using HIV-based pseudoviruses expressing the spike of different SARS-CoV-2 variants and analyze them longitudinally using mixed-effects models. Long-term neutralizing activity is stable beyond 1 year after infection in mild/asymptomatic and hospitalized participants. However, longitudinal models suggest that hospitalized individuals generate both short- and long-lived memory B cells, while the responses of non-hospitalized individuals are dominated by long-lived B cells. In both groups, vaccination boosts responses to natural infection. Long-term (.
publishDate	2022
dc.date.none.fl_str_mv	2 2022-01-01 2022 2022-01-01
dc.type.none.fl_str_mv	Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://ddd.uab.cat/record/257275 https://dx.doi.org/urn:doi:10.1016/j.xcrm.2022.100523
url	https://ddd.uab.cat/record/257275 https://dx.doi.org/urn:doi:10.1016/j.xcrm.2022.100523
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.relation.none.fl_str_mv	Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI17/01518 Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI20/00093 Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18/01332
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.source.none.fl_str_mv	reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona
instname_str	Universitat Autònoma de Barcelona
reponame_str	Dipòsit Digital de Documents de la UAB
collection	Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869415962152796160
score	15,301603

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

Similares en LA Referencia